Dr. Sledge on the Quantitative Measurement of Mutations

George W. Sledge, Jr., MD
Published: Thursday, Mar 21, 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses measuring mutations in human cancers quantitatively.

Sledge says that the new "currency" for measuring a patient's genome is the number of mutations in their cancer. There is a thousandfold difference between the least mutated and the most mutated of human cancers. This vast difference, Sledge says, impacts how a patient will respond to therapy.

As for doctors, who have spent their entire careers analyzing qualitative aspects of oncology, this new quantitative outlook is a big change. Patients with many mutations, such as those with triple-negative breast cancer, also have a greater chance of resisting drug therapies.
 
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses measuring mutations in human cancers quantitatively.

Sledge says that the new "currency" for measuring a patient's genome is the number of mutations in their cancer. There is a thousandfold difference between the least mutated and the most mutated of human cancers. This vast difference, Sledge says, impacts how a patient will respond to therapy.

As for doctors, who have spent their entire careers analyzing qualitative aspects of oncology, this new quantitative outlook is a big change. Patients with many mutations, such as those with triple-negative breast cancer, also have a greater chance of resisting drug therapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x